Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Celldex Therapeutics, Inc.

Market Cap 2.3B 2B 1.84B 1.73B 3.23B 221B 3.29B 21.98B 8.51B 106B 8.65B 8.46B 370B P/E Ratio 2026 *
-6.76x
P/E Ratio 2027 * -6.72x
Enterprise Value 1.72B 1.49B 1.38B 1.29B 2.41B 165B 2.46B 16.41B 6.35B 79.37B 6.46B 6.32B 276B EV / Sales 2026 *
653x
EV / Sales 2027 * 150x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -
1 day+2.04%
1 week-0.05%
Current month-4.82%
1 month-7.33%
3 months-4.21%
6 months+7.07%
Current year+10.14%
1 week 28.38
Extreme 28.38
30.34
1 month 28.38
Extreme 28.38
33.08
Current year 22.33
Extreme 22.33
35.79
1 year 19.52
Extreme 19.52
35.79
3 years 14.4
Extreme 14.4
53.18
5 years 14.4
Extreme 14.4
57.2
10 years 1.5
Extreme 1.5
75.3
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 2014-07-29
Chief Executive Officer 64 2008-08-31
Director of Finance/CFO 55 2009-03-31
Director TitleAgeSince
Director/Board Member 64 2008-11-30
Chairman 80 2025-06-04
Director/Board Member 93 2008-02-29
Date Insider Type Main position Quantity % Market Cap.
01-01Fiscal year

Chief Financial Officer

9,634 0.0145%
12-14Fiscal year

Executive/Senior Manager

38,666 0.0582%
12-03Sell

General Counsel

4,166 0.0063%
Change 5-day change 1-year change 3-year change Capi.($)
+2.03%-0.05%+46.50%-19.34% 2.3B
-1.40%+0.12%-14.73%-12.42% 43.68B
+3.67%-4.23%+265.53%+489.10% 30.65B
-1.22%-3.36%+13.71%-14.77% 30.4B
-0.97%-6.62%-0.39%+22.61% 29.31B
-0.66%-7.13%+7.59%+12.76% 24.2B
+1.64%+3.31%+56.74%+117.34% 13.3B
+3.80%-0.40% - - 13.03B
-1.65%-1.08%+7.92%+8.03% 13.21B
+1.10%-1.58%+104.31%+77.61% 12.12B
Average +0.70%-1.01%+54.13%+75.66% 21.22B
Weighted average by Cap. +0.33%-1.44%+51.79%+88.04%

Financials

2026 *2027 *
Net sales 2.63M 2.29M 2.11M 1.97M 3.69M 252M 3.77M 25.14M 9.73M 122M 9.89M 9.68M 423M 11.96M 10.38M 9.57M 8.97M 16.75M 1.15B 17.1M 114M 44.19M 552M 44.91M 43.94M 1.92B
Net income -330M -286M -264M -247M -462M -31.6B -472M -3.15B -1.22B -15.23B -1.24B -1.21B -52.97B -370M -322M -296M -278M -519M -35.47B -530M -3.54B -1.37B -17.1B -1.39B -1.36B -59.46B
Net Debt -584M -507M -467M -438M -818M -55.93B -835M -5.57B -2.16B -26.96B -2.19B -2.15B -93.74B -507M -440M -406M -380M -711M -48.58B -725M -4.84B -1.87B -23.42B -1.9B -1.86B -81.43B
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
198
Date Price Change Volume
26-06-11 29.92 $ +1.93% 440,820
26-06-10 29.35 $ -0.84% 490,422
26-06-09 29.60 $ +3.64% 616,942
26-06-08 28.56 $ -0.21% 629,704
26-06-05 28.62 $ -4.38% 1,273,657
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
29.35USD
Average target price
57.53USD
Spread / Average Target
+96.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLDX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!